Carbohydrate Antigen-125–Guided Therapy in Acute Heart Failure

Dharmarajan, 2015, Trajectories of risk after hospitalization for heart failure, acute myocardial infarction, or pneumonia: retrospective cohort study, BMJ, 350, h411, 10.1136/bmj.h411 Ambrosy, 2014, The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries, J Am Coll Cardiol, 63, 1123, 10.1016/j.jacc.2013.11.053 Krumholz, 2013, Relationship between hospital readmission and mortality rates for patients hospitalized with acute myocardial infarction, heart failure, or pneumonia, JAMA, 309, 587, 10.1001/jama.2013.333 Januzzi, 2013, Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are useful in heart failure management, Circulation, 127, 500, 10.1161/CIRCULATIONAHA.112.120485 Troughton, 2014, Natriuretic peptide-guided heart failure management, Eur Heart J, 35, 16, 10.1093/eurheartj/eht463 Pfisterer, 2009, BNP-guided vs symptom-guided heart failure therapy: BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial, JAMA, 301, 383, 10.1001/jama.2009.2 Felker, 2011, Diuretic strategies in patients with acute decompensated heart failure, N Engl J Med, 364, 797, 10.1056/NEJMoa1005419 Di Somma, 2015, Drug therapy for acute heart failure, Rev Esp Cardiol (Engl Ed), 68, 706, 10.1016/j.recesp.2015.02.019 Parrinello, 2008, The pathophysiology of acute heart failure: the key role of fluid accumulation, Am Heart J, 156, e19, 10.1016/j.ahj.2008.04.031 Gheorghiade, 2010, Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine, Eur J Heart Fail, 12, 423, 10.1093/eurjhf/hfq045 Peacock, 2010, Current techniques of fluid status assessment, Contrib Nephrol, 164, 128, 10.1159/000313726 Marcus, 2014, Current approaches and challenges in managing and monitoring treatment response in ovarian cancer, J Cancer, 5, 25 Núñez, 2014, Clinical utility of antigen carbohydrate 125 in heart failure, Heart Fail Rev, 19, 575, 10.1007/s10741-013-9402-y Núñez, 2010, Improvement in risk stratification with the combination of the tumour marker antigen carbohydrate 125 and brain natriuretic peptide in patients with acute heart failure, Eur Heart J, 31, 1752, 10.1093/eurheartj/ehq142 D'Aloia, 2003, Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and short-term prognosis, J Am Coll Cardiol, 41, 1805, 10.1016/S0735-1097(03)00311-5 Núñez, 2012, Antigen carbohydrate 125 and brain natriuretic peptide serial measurements for risk stratification following an episode of acute heart failure, Int J Cardiol, 159, 21, 10.1016/j.ijcard.2011.02.001 Miñana Escrivá, 2012, Carbohydrate antigen 125 serial measurements after an admission for acute heart failure and risk of early readmission, Med Clin (Barc), 139, 479, 10.1016/j.medcli.2011.05.029 Núñez, 2016, Long-term serial kinetics of N-terminal pro B-type natriuretic peptide and carbohydrate antigen 125 for mortality risk prediction following acute heart failure, Eur Heart J Acute Cardiovasc Care Núñez, 2012, Differential mortality association of loop diuretic dosage according to blood urea nitrogen and carbohydrate antigen 125 following a hospitalization for acute heart failure, Eur J Heart Fail, 14, 974, 10.1093/eurjhf/hfs090 Núñez, 2011, Benefits of statin therapy according to plasma antigen carbohydrate 125 following an admission for acute heart failure, Rev Esp Cardiol, 64, 1100, 10.1016/j.recesp.2011.05.029 Núñez, 2015, Prognostic effect of carbohydrate antigen 125-guided therapy in patients recently discharged for acute heart failure (CHANCE-HF). Study design, Rev Esp Cardiol, 68, 121, 10.1016/j.recesp.2014.03.018 Dickstein, 2008, Eur Heart J, 29, 2388, 10.1093/eurheartj/ehn309 McMurray, 2012, Eur Heart J, 33, 1787, 10.1093/eurheartj/ehs104 Royston, 2011, The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt, Stat Med, 30, 2409, 10.1002/sim.4274 Ghosh, 2000, Nonparametric analysis of recurrent events and death, Biometrics, 56, 554, 10.1111/j.0006-341X.2000.00554.x Rogers, 2014, Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved, Eur J Heart Fail, 16, 33, 10.1002/ejhf.29 Rizopoulos, 2012 McMurray, 2009, Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis, Circulation, 120, 2188, 10.1161/CIRCULATIONAHA.109.849117